First-in-class Anti-CD47 Fusion Protein DSP107 Under Investigation in AML and MDS
November 10th 2021
The FDA cleared an investigational new drug application for a phase 1b clinical trial examining DSP107, a first-in-class anti-CD47 fusion protein, in patients with acute myeloid leukemia and myelodysplastic syndrome.